Vertex Pharmaceuticals (VRTX) EBT (2009 - 2026)

Vertex Pharmaceuticals' EBT history runs 18 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• In Q1 2026, EBT rose 71.54% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $5.2 billion (up 1820.75% YoY), while the FY2025 annual figure was $4.6 billion, up 1768.49% from the prior year.
• EBT was $1.3 billion for Q1 2026 at Vertex Pharmaceuticals, down from $1.3 billion in the prior quarter.
• In the past five years, EBT ranged from a high of $1.3 billion in Q4 2025 to a low of -$3.4 billion in Q2 2024.
• Historically, EBT has averaged $868.0 million across 5 years, with a median of $1.2 billion in 2023.
• The sharpest annual moves came in 2022 and 2024: EBT surged 2417.65% in 2022, then slumped 391.97% in 2024.
• A 5-year view of EBT shows it stood at $1.1 billion in 2022, then grew by 6.58% to $1.1 billion in 2023, then slipped by 0.97% to $1.1 billion in 2024, then gained by 17.11% to $1.3 billion in 2025, then declined by 5.87% to $1.3 billion in 2026.
• The last three EBT figures came in at $1.3 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.